Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET. The European Commission (EC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results